Kalbe Farma Tbk PT banner

Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 950 IDR -1.04% Market Closed
Market Cap: Rp44.5T

EV/OCF

11.9
Current
25%
Cheaper
vs 3-y median of 15.7

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
11.9
=
Enterprise Value
Rp39.9T
/
Operating Cash Flow
Rp3.3T

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
11.9
=
Enterprise Value
Rp39.9T
/
Operating Cash Flow
Rp3.3T

Valuation Scenarios

Kalbe Farma Tbk PT is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (15.7), the stock would be worth Rp1 260.19 (33% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-47%
Maximum Upside
+40%
Average Upside
13%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 11.9 Rp950
0%
3-Year Average 15.7 Rp1 260.19
+33%
5-Year Average 16.6 Rp1 331.42
+40%
Industry Average 14.8 Rp1 186.27
+25%
Country Average 6.3 Rp501.96
-47%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
ID
Kalbe Farma Tbk PT
IDX:KLBF
43T IDR 11.9 11.8
US
Eli Lilly and Co
NYSE:LLY
875.9B USD 54.1 42.4
US
Johnson & Johnson
NYSE:JNJ
563.9B USD 24 26.8
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15 19.8
UK
AstraZeneca PLC
LSE:AZN
234.5B GBP 22.4 30
US
Merck & Co Inc
NYSE:MRK
294.7B USD 19.8 16.1
CH
Novartis AG
SIX:NOVN
228B CHF 15.7 20.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 10.3 11.2
US
Pfizer Inc
NYSE:PFE
156.7B USD 17.5 20.2
US
Bristol-Myers Squibb Co
NYSE:BMY
121.1B USD 10.9 17.2
P/E Multiple
Earnings Growth PEG
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/E: 21.6
11.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.4
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.8
8%
3.4
CH
Roche Holding AG
SIX:ROG
19.8
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
30
25%
1.2
US
Merck & Co Inc
NYSE:MRK
16.1
14%
1.2
CH
Novartis AG
SIX:NOVN
20.3
14%
1.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
0%
N/A
US
Pfizer Inc
NYSE:PFE
20.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1

Market Distribution

In line with most companies in Indonesia
Percentile
66th
Based on 727 companies
66th percentile
11.9
Low
0 — 3.6
Typical Range
3.6 — 14.1
High
14.1 —
Distribution Statistics
Indonesia
Min 0
30th Percentile 3.6
Median 6.3
70th Percentile 14.1
Max 1 136 900.3

Kalbe Farma Tbk PT
Glance View

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 375.51 IDR
Undervaluation 31%
Intrinsic Value
Price Rp950
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett